Literature DB >> 34212166

Nanoengineering of a newly designed chlorin e6 derivative for amplified photodynamic therapy via regulating lactate metabolism.

Xiaohan Qin1, Mengzhu Zhang1, Xu Hu1, Qian Du1, Zhipeng Zhao1, Yue Jiang1, Yuxia Luan1.   

Abstract

Chlorin e6 (Ce6) is a widely utilized photosensitizer in photodynamic therapy (PDT) against tumor growth, but its hydrophobic feature and the hypoxia in the tumor microenvironment greatly compromise its therapeutic efficacy. To address the issues, here we designed a new Ce6 derivative (TCe6) by coupling Ce6 with amphiphilic d-α-tocopherol polyethylene glycol 1000 succinate (TPGS), endowing Ce6 with an excellent amphiphilic feature. In particular, the overall reactive oxygen species (ROS) generation by TCe6 was significantly enhanced because TPGS could interact with mitochondrial complex II to induce extra ROS production, amplifying the total ROS production under PDT. Inspired by the unique property of α-cyano-4-hydroxycinnamate (CHC) in regulating lactate metabolism to spare more intracellular oxygen for PDT, TCe6 was further co-assembled with CHC to construct TCe6/CHC nanoparticles (NPs) for addressing the insufficient oxygen issue in PDT. The as-prepared TCe6/CHC NPs not only increased the efficiency of cell internalization but also improved the solubility and stability of Ce6 and CHC. Thanks to the extra ROS production by the TPGS unit, the amphiphilic feature of TCe6 and the CHC-mediated hypoxia microenvironment, the TCe6/CHC NPs demonstrated excellent PDT against tumor growth. This work provided a versatile strategy to solve the current bottleneck in photosensitizer-based PDT, holding great promise for the design of advanced photodynamic nanoplatforms.

Entities:  

Year:  2021        PMID: 34212166     DOI: 10.1039/d1nr01083b

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  4 in total

Review 1.  Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.

Authors:  Bin Ji; Minjie Wei; Bin Yang
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

2.  A pH-responsive complex based on supramolecular organic framework for drug-resistant breast cancer therapy.

Authors:  Yun-Chang Zhang; Pei-Yu Zeng; Zhi-Qiang Ma; Zi-Yue Xu; Ze-Kun Wang; Beibei Guo; Feng Yang; Zhan-Ting Li
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

3.  Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer.

Authors:  Jing Wang; Yan Zhang; GuangPeng Zhang; Li Xiang; HaoWen Pang; Kang Xiong; Yun Lu; JianMei Li; Jie Dai; Sheng Lin; ShaoZhi Fu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

4.  Hispolon-Loaded Liquid Crystalline Nanoparticles: Development, Stability, In Vitro Delivery Profile, and Assessment of Hepatoprotective Activity in Hepatocellular Carcinoma.

Authors:  Mohammad Javed Ansari; Mahfoozur Rahman; Khalid S Alharbi; Waleed M Altowayan; Ahmed Mahmoud Abdelhaleem Ali; Waleed H Almalki; Md Abul Barkat; Tanuja Singh; Shehla Nasar; Md Habban Akhter; Sarwar Beg; Hani Choudhry
Journal:  ACS Omega       Date:  2022-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.